Thank you.
Good afternoon, and thanks, everyone, for joining us for the Fate Therapeutics Second Quarter 2022 Financial Results Call.
p.m. X:XX after Shortly
we be press section found Press website today, results, of with which under can on Releases. issued Time release a these our Eastern the Investors
Form and can found June our In website quarter of Investors be for under filed thereafter was Financial on ended Information. addition, shortly XX, XX-Q section XXXX, our the the
questions circumstances the disclaims call made update Except as Reform made they the facts these that of Act historical differ statements statements forward-looking our to Fate that the forward-looking the we with market I'd for materially by statements earnings and the provisions the change. after issued company's forward-looking as Before filed which not events these today Undue statements. of risks management to for safe begin, can ended as in those conference SEC like was of date the Securities of and be except statements to circumstances. on the responses under such well statements forward-looking forward-looking included any information, the to press may release as the of uncertainties today. are XXXX. risk Litigation remind close These from and Please as statements or this law, are by the to required everyone forward-looking results on cause underlying disclaimer reliance harbor actual facts, see Form Therapeutics XX, that obligation Private speak involve statements, on statement future quarter should XX-Q reflect June XXXX, placed in only factors
programs NK Officer; Ed Chief iPSC-derived we to will with Dr. Valamehr, the call our achieve striving Wayne today's off-the-shelf cancer. Research X cell Chief during highlight and the Financial Medical on Today, Dulac, treatment Officer; Dr. for Chu, of objectives and our key are Officer. T Chief our me we next Bob Development are our and months Joining
to near-term diagnosed late-stage assess malignancy for Our FTXXX+R-CHOP aggressive our seeking community relapsed/refractory patients advance into T chemotherapy. newly we are of conditioning to a CY/FLU in top cell with development setting treating and remains without focus the feasibility franchise, where lymphoma
a We approaching engineered candidates cell IND readiness sharing next continuing platform the immunotherapy to X aggressive manufacture during also pivotal protocol and to functionality our the combination I dose FTXXX and continue is we refractory our NK the study And data at and of look to a to dose we increase to that clinical rituximab, we are of unveiling escalation cancer dose programs to In with a and the permitted with with engineered cell and ONO are iPS-derived of initiation profile cohorts Phase X our clear the cancer engineered to our technology where Janssen production dose escalation for of X inflection clearance treatment billion from schedule. believe further allows Under our lymphoma, are submission. multiple dose manufacturing regulatory great treatment. programs B-cell cohorts CAR therapeutic make iPS-derived novel new evaluate challenge upon hurdles cycles development forward And for programs to across of set and dose for cells further cell maximize patient schedule any cells T to IND million are NK points single billion CAR and months. our We our cohorts have dose in for observed initiated with advance under collaborations NK patients cohort per in dosing winning donor-derived strides expansion to cell load. therapies, key end, multiplexed X-dose up To multiple cell further incorporate are that evaluate clinical, in dose. operations. continuing cell Eligible poised And to in safety pursuit single enrollment at T further a towards relapsed to favorable and X.X of for numerous iPSC products. per at at receive And clinical XXX we first-in-human synthetic index. off-the-shelf we continue X.X engineered multiplex toxicities, and open mass the per to cells of and additional dose. dose-limiting of we
lymphoma, for On agenda the pathways quarter. scheduled available with a FDA may meeting regulatory front, our for B-cell that including of refractory patients relapsed prior or in treatment the is programs FTXXX multidisciplinary FDA-approved off-the-shelf discussion be registrational The T for B includes cell third Type the RMAT CDXX-targeted have is our disease iPS-derived multiple cell CAR relapsed aggressive whose with following therapy. refractory to NK
is aseptic facility. research input and mass clinical, among Across remain produce we corporate approval pathway continue study pillars the from drug and and of relapsed/refractory to to chart months. dosing company's for update operations, in with a continue The pivotal and IPS-derived corporate facility over regulatory our on have a cell toward commercial look the Importantly, to these optimize NK product we franchise GMP designed headquarters, California X schedule for GMP coming With full quality, engineering programs process progress execution validation with supply runs to to is the are for forward initial standard pivotal development conduct drug patients of comprehensive campus from and our poised integration launch for Poway, no FTXXX our to outcomes. patients, and is teams. We lymphoma treatment the the our well-positioned regulatory FDA operations, products poor facility operational indicate state-of-the-art to and completed manufacturing regulatory manufacturing, B-cell and now studies state-of-the-art as technical for located these these multi-drug ongoing. product of the key production and therapies opened extremely has manufacturing real-world respect providing allowing in that for data to located available successfully
also up in activities to sites, of the administered X begin patients relapsed immunochemotherapy to schema that we cell-based community B-cell have and with barrier might a chemotherapy therapeutic the to assessing in patients FTXXX cell outsized with chemotherapy. cell-based brings lymphoma, to that with therapies combination an with significant worked treating newly of with conditioning lymphoma add-on cancer treatment setting To heavily from X investigators start-up diagnosed community clinical administration FTXXX+R-CHOP many finalize refractory setting significant we been The to conditioning FTXXX+R-CHOP with in the key cycle In at the allows aggressive with and in patient value the X immunotherapy. R-CHOP. setting ongoing Each conditioning with of immunotherapies flu dose is Study addition reach newly chemotherapy off-the-shelf FTXXX each treatment XXXX. and benefit aggressive we multiple earlier end, submitted who standard access. for are And for patients may community FTXXX that R-CHOP, doses expect clinical transformative pretreated half diagnosed We to of are in the to of administration seeking frontline broader lymphoma to in hold CY/FLU the cancer patients. The the the accompanies that delivering leaders of second has delivery use allogeneic protocol standard regimens with patients of believe a FTXXX as protocol opinion intense both treatment outcomes to with patients the to of regimen. first-line autologous IND. for
unveiled the In field addition, to research as substantially intact and system persistence candidates part or to of requirement At into of reach potentiate a cell-based harness for our transferred our Cancer chemotherapy patient's of immunotherapy the Research integration cancer American that their immune eliminate new adoptively functional and in patients we the earlier elements can April, conditioning quest to in synthetic for in care, Association reduce cells. our for product activity continue potential alloreactive alloimmune chemotherapy. a patient T which preclinical in NK conditioning the activity armed proof vitro showed without ADR immune persist ADR, we antitumor In These that therapies cells. models, potent in cell expand, of concept and activated persist proprietary maintain induce presence X-XBB have receptor defense provide expressing preclinical selectively undergo to cells. activity requiring to of ADR that the antitumor targets data uniquely cells arm we iPSC-derived and or
expect new data During present and of preclinical a we XXXX, into to NK our ADR technology the highlight cell product next-generation second half for its integration candidate.
to collaborations Janssen and Turning with Ono. our
its stage CAR-T clinical tumors. in candidates each second an profits And towards patients targeting co-commercialize Janssen and to show are advanced Jansen and to IPS-derived under we worldwide bringing and are maintain the IND the have malignancies where program, collaboration hematologic antigen antigen NK programs option exercise antigen equally to X treatment to its two points development antigen fee, to U.S. poised a payment inflection are entered exercised of solid are Janssen, decision. for of share we products momentum of into multiplexed cell hematologic Under a of reaching Janssen CAR commercialize and subject contributed and to option option submission. initiate and $XX continue of losses a We IND two key collaboration collaboration multiple program May, advance We on collaboration to novel and million strong an each payment under maintains fee first in to domains option, in engineered to the designated exercise In directed of XXXX, in triggering and our tumors. solid prior program. submission of opt-in products binding programs, to directed which April malignancies to program. to right which now antigen with tumor-associated the
these a prepare conduct novel and cell for the to CAR for we Ono option working collaboration solid the off-the-shelf products has worldwide domains two into programs currently one clinical with products. preclinical option iPS-derived with development NK co-develop tumor-associated to Under of subject collaboration September antigen each specified an Ono our therapy. And are in of IND to XXXX, development of payment fee T-cell Janssen the contributed its CAR applications: the collaboration and co-commercialize retains X submit milestone, and achievement one U.S. exercise antigen to of Upon for Europe. maintain right and Ono iPS-derived commercialization. off-the-shelf targeting entered binding We
collaboration candidate of Ono initiate IND-enabling its the initiated fee. time to option activities We to are the multiplexed this the have for now specified option subject and payment milestone positioned at right T its exercise the achieve a CAR and cell year, has preclinical master to engineered later the iPSC-derived which of cell exercise generation bank
collaboration cell we Ono antigen tumor solid tumor together program antigen both and working second of on program, success candidates. with the Given expanded the a to we have and achieved first CAR in development NK second our CAR-T add quarter the a collaboration solid to include
we've multiplexed very success are and engineered Ono tumors. CAR NK for candidates IPS-derived liquid solid pleased and We in with product the developing with achieved and both cell Janssen CAR-T
milestones and are connection over poised exercises in option the advance and We submission Ono multiple toward with by months. achieve IND Janssen collaboration significant X products next to
effectiveness the including the Annual T Meeting for SITC, innovation in we the damage Annual CAR Phase tumors. and of I iPSC-derived a CAR elements pleased announce cell such tumors. NK as we immunotherapies, incorporation pipeline building solid leadership cell engineered solid targeting our of in overcome designed proteins, that tumor under and we stress, will FTXXX, treated and including to and of of I franchise synthetic first our study expression of the been multiplexed is showcase at the Meeting the transformation solid ever the limit cadets, MICB Class In half IPS-derived malignancies T forward our progress cancer invest A look iPS-derived escape At B. in and am Society cell MICA cellular deep to During immunosuppressive I to XXXX, homing, for November American barriers highlighting second major the cell take and Immunotherapy Society where quarter, microenvironment. to multicenter tumor and of of critical hematologic patient new induced product December. tumors NK incorporates Hematology that clinical we development second proteins many at company's on first the to program by opportunity and for complex reported has a CAR of the tumor therapy, in the continue FTXXX through or Cancer solid NK High cell our in related development for novel which of histocompatibility
include the and novel, diverse cell-based is across share malignancy IND-enabling overcome promising studies, to of by We is and to ASH, antigens an modalities antibody of escape. incorporates pipelines promote hematologic to are resistant of CAR to cell one that common the have microenvironment. However, CAR-T data solid to combination proteins tumors, proteolytic of in other represents the with these most for candidate's escape. to T immunotherapy IPS-derived our induce action, sophisticated our excited FTXXX shedding therapy platform. which [Technical we in MICB, believe candidates towards product tumor of for is and mechanism a therefore ability proprietary enabled including clinical cancer We which synthetic in trafficking believe novel mechanism activation iPS-derived signaling Difficulty] alpha-X domains MICA monoclonal product X and a of product shedding strategy that and target the uniquely are uniquely overcome cell tumor iPSC we which tumor alpha-X alpha-X product solid targets tumor candidate also domain At advancing response tumors the its heterogeneity, franchises. repressive
as to to with addition biolelic the into to look a with CAR our therapy exhaustion. in FTXXX. insertion multiple that is of data and transgene anti-CDXX cell lymphoma, expression. T-cell investigator program, Not clinical enthusiasm product novel iPS-derived FTXXX T-cell candidate. monotherapy complete receptor daratumumab both the And of its clinical FTXXX, disruption unique incorporates it alpha balance undergo franchise FTXXX and comprised we domain is T the cell cell T-cell iPS-derived investigation. with AML, construct CAR in the a we fronts, of truly combination On costimulatory a our in only off-the-shelf cells myeloma, a single-dose novel to low-dose activation constant designed first-in-class to In high is cohorts we XXX of first-ever profile dose. setting dose are BCMA per to an relapsed/refractory see potentiate forward locus to In continue NK to T for and well patients sharing is CAR X cohorts our endogenous conferred with first dose our enabling of potential combining and reducing functional cells quarter dose, I of look assess to forward is from would multi-dose now multiantigen turn at persistence ongoing in immune setting financial cohorts, FTXXX call in where multiple and schedules, the activity for competition seeing Ed like as CDXX escalation daratumumab, now FTXXX. finally, FTXXX of X.X with targeting highlight we the cytokines second BCMA further binder with while billion in initial multiple the benefits over as to including the to treating And the the results. relapsed/refractory receptor in of treatment
